Selection of Cancer Stem Cell–Targeting Agents Using Bacteriophage Display
- 1 January 2022
- book chapter
- Published by Springer Nature
- Vol. 2394, 787-810
Abstract
There is a growing need to develop tumor targeting agents for aggressive cancers. Aggressive cancers frequently relapse and are resistant to various therapies. Cancer stem cells (CSCs) are believed to be the cause of relapse and the aggressive nature of many cancers. Targeting CSCs could lead to novel diagnostic and treatment options. Bacteriophage (phage) display is a powerful tool developed by George Smith in 1985 to aid in the discovery of CSC targeting agents. Phage display selections are typically performed in vitro against an immobilized target. There are inherent disadvantages with this technique that can be circumvented by performing phage display selections in vivo. However, in vivo phage display selections present new challenges. A combination of both in vitro and in vivo selections, however, can take advantage of both selection methods. In this chapter, we discuss in detail how to isolate a CSC like population of cells from an aggressive cancer cell line, perform in vivo and in vitro phage display selections against the CSCs, and then characterize the resulting phage/peptides for further use as a diagnostic and therapeutic tool.Keywords
This publication has 38 references indexed in Scilit:
- Identification of targeting peptides for ischemic myocardium by in vivo phage displayJournal of Molecular and Cellular Cardiology, 2011
- In Vitro and In Vivo Evaluation of 64 Cu-Radiolabeled KCCYSL Peptides for Targeting Epidermal Growth Factor Receptor-2 in Breast CarcinomasCancer Biotherapy and Radiopharmaceuticals, 2010
- Identification of a Cardiac Specific Protein Transduction Domain by In Vivo Biopanning Using a M13 Phage Peptide Display Library in MicePLOS ONE, 2010
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerOncogene, 2010
- Targeted proteomic strategy for clinical biomarker discoveryMolecular Oncology, 2008
- Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and AngiogenesisJournal of Clinical Oncology, 2008
- CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosisBritish Journal of Cancer, 2008
- Why molecules move along a temperature gradientProceedings of the National Academy of Sciences, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Making antibody fragments using phage display librariesNature, 1991